Tim Murawski is the President and Chief Commercial Officer of Augmedics. He has been a leader in the medical technology industry for many years. He has played a major role in developing and commercializing Augmedics’ groundbreaking x-ray vision technology. 

This article will take a closer look at healthcare expert Tim Murawski´s career and his work with Augmedics. We will also discuss the company’s upcoming clinical trials and how they plan to revolutionize the field of ophthalmology. Tim Murawski is a graduate of the University of Michigan. He began his career in the medical device industry at Johnson & Johnson, where he worked for more than 10 years in various marketing and sales roles. 

He then joined Boston Scientific, where he served as the Vice President of Marketing for the Cardiology and Peripheral Interventions business unit. In this role, he was responsible for global marketing strategy and execution. After more than 20 years in the medical device industry, Tim Murawski joined Augmedics in 2016. Augmedics is a clinical-stage medical technology company developing the world’s first x-ray vision system for use in ophthalmology. 

The company’s proprietary technology, called the Augmented Visualization System (AVS), is designed to provide surgeons with real-time x-ray vision during surgery. This would allow them to see through tissue and identify anatomical structures that are not visible to the naked eye. Augmedics is currently conducting clinical trials of the Augmented Visualization System in Europe and Israel. Tim Murawski explains that the company planned to initiate a pivotal clinical trial in the United States in 2019. If the AVS receives FDA approval, it has the potential to revolutionize the field of ophthalmology by providing surgeons with unprecedented levels of visibility during surgery.